Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07155668 · ClinicalTrials.gov registry record · Phase 3
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
A Phase 3 study of Thyroid Eye Disease, sponsored by Viridian Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
- 13
- Study locations
NCT07155668: Active Phase 3 study of Thyroid Eye Disease, sponsored by Viridian Therapeutics.
NCT07155668 is a Phase 3 study of Thyroid Eye Disease that is active but no longer recruiting, run by Viridian Therapeutics. The registered enrollment target is 87 participants, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (14% lower). The trial reports 13 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07155668, a Phase 3 study of Thyroid Eye Disease, is active but no longer recruiting, sponsored by Viridian Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)
Primary Outcome
Treatment Emergent Adverse Event (TEAE) incidence rate
Conditions Studied
Interventions
- DRUG VRDN-003
- DEVICE Autoinjector
Study Locations (13)
Florida
- C&A Clinical Trials Corp - Cape Coral
- Ilumina Medical Research - Kissimmee
- Med-Care Research - Miami
- Continental Clinical Research, llc - Miami
- Hype Clinical Research, LLC - Miami
Michigan
- Fraser Eye Center - Fraser
- Kahana Oculoplastic and Orbital Surgery - Livonia
Texas
- Baylor College of Medicine, Alkek Eye Center - Houston
- Neuro Eye Clinical Trials INC - Houston
California
- United Medical Research Institute - Inglewood
Illinois
- Advanced Quality Medical Research, LLC - Orland Park
Massachusetts
- Ophthalmic Consultants of Boston - East Weymouth
Nevada
- Vector Clinical Trials - Sparks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
What the registry record for NCT07155668 still lists
NCT07155668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which VRDN-003 is the first listed.
NCT07155668 lists 13 locations in 7 states (Florida, Michigan, Texas).
Frequently Asked Questions
What is clinical trial NCT07155668 about?
NCT07155668 is a clinical study titled "A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)". This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)
What is the current status of trial NCT07155668?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2025-07-01. Estimated completion is 2026-11.
What conditions does trial NCT07155668 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT07155668?
The interventions under investigation include: VRDN-003 (DRUG), Autoinjector (DEVICE).
Who is sponsoring clinical trial NCT07155668?
This trial is sponsored by Viridian Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07155668 being conducted?
This trial has 13 study locations across California, Florida, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07155668's enrollment target sits among peer trials
87 12th of 15 higher than 4 of 15 other Thyroid Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI